AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia

Chimeric antigen receptor (CAR) T-cell therapy is the most active field in immuno-oncology and brings substantial benefit to patients with B cell malignancies. However, the complex procedure for CAR T-cell generation hampers its widespread applications. Here, we describe a novel approach in which hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nawaz, Waqas, Huang, Bilian, Xu, Shijie, Li, Yanlei, Zhu, Linjing, Yiqiao, Hu, Wu, Zhiwei, Wu, Xilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222347/
https://www.ncbi.nlm.nih.gov/pubmed/34162832
http://dx.doi.org/10.1038/s41408-021-00508-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222347/
https://www.ncbi.nlm.nih.gov/pubmed/34162832
http://dx.doi.org/10.1038/s41408-021-00508-1

Ejemplares similares